Trillium Therapeutics Inc. Made Headway
Thu, Jan 09, 2020 at 05:30 PM
Trillium Therapeutics Inc. (TRIL:NASDAQ) rocketted at $2.89, a gain of 94%. The stock appeared on our News Catalysts scanner on Thu 09 Jan 20 at 03:19 PM in the 'BIOTECH' category. From Tue 17 Dec 19, the stock recorded 64.29% Up Days and 53.33% Green Days
About Trillium Therapeutics Inc. (TRIL:NASDAQ)
Trillium Therapeutics Inc is an immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc and CD200 monoclonal antibody targets immuno regulatory pathways that tumor cells exploit to evade the host immune system.
Top 10 Gainers:
- Applied Genetic Technologies Corporation (AGTC:NASDAQ), 122.84%
- Trillium Therapeutics Inc. (TRIL:NASDAQ), 93.96%
- Genetic Technologies Limited (GENE:NASDAQ), 45.09%
- Titan Pharmaceuticals, Inc. (TTNP:NASDAQ), 36.53%
- Novus Therapeutics, Inc. (NVUS:NASDAQ), 35.71%
- La Jolla Pharmaceutical Company (LJPC:NASDAQ), 34.96%
- The Peck Company Holdings, Inc. (PECK:NASDAQ), 34.71%
- Capricor Therapeutics, Inc. (CAPR:NASDAQ), 33.59%
- KemPharm, Inc. (KMPH:NASDAQ), 31.72%
- Proteon Therapeutics, Inc. (PRTO:NASDAQ), 30.5%